21 results about "Mycobacterial cell" patented technology

The invention provides a method for improving cell permeability of mycobacterium neoaurum, a mycobacterium neoaurum engineering bacterium and an application of the mycobacterium neoaurum engineering bacterium in preparation of 9 alpha-hydroxyandrostane-4-ene-3, 17-diketone (9-OHAD). Biotransformation of phytosterol into high-value steroid intermediates such as 9-OHAD in mycobacteria is a footstone of steroid drugs. However, the limited permeability of its dense cell wall of Mycobacterium severely hinders the effective intracellular transport of phytosterols and its bioconversion to 9-OHAD. The endogenous synthesis capability and exogenous circulation capability of mycobacterium neoaurum trehalose are destroyed through gene knockout, the permeability of cells is improved, the molar conversion rate of 9-OHAD is increased to 65.7% from 44.7%, the extracellular production of 9-OHAD is also improved, the extracellular yield of 9-OHAD is increased to 32.1% from 12%, and subsequent separation and purification are facilitated.

The invention describes a series of Benzo[de]isoquinoline-1,3-dione-based fluorophore probes, synthetic processes for the same, and their application for anti-tuberculosis potency and detecting pathogenic or non-pathogenic bacteria from the Mycobacterium genus. The fluorophore probe comprises a dye, a linker, and a benzothiazinone (BTZ)-based targeting group for anchorage to mycobacterial cell wall enzyme DprE1. The dye-BTZ fluorophore probe inhibits the DprE1 enzyme function and further inhibits the growth of Mycobacterium tuberculosis. It allows the signal to be retained and, hence, the single cells of Mycobacterium to be labeled. The conjugate exhibits solvatochromic behavior with respect to the environment. A detectable fluorescent signal is produced by the dye once it is incorporated into the bacterial cell wall because of the change in the local environment.

The present invention relates to the oxazolidinone compound of Formula (I): and pharmaceutically acceptable salts thereof. The present invention also relates to compositions containing the compound of Formula (I). The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering a therapeutically effective amount of Formula (I) and / or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and / or salt.

The present disclosure features compositions and methods for the treatment of actinomycetia (e.g., corynebacteriales) infections, e.g., caused by mycobacterial cells, residing within a host cell (e.g., a mammalian cell, e.g., immune cell, e.g., macrophage or dendritic cell). The compositions and methods include delivering a mixture of lytic enzymes to specifically target the cell envelope of a group of related bacterial species in the intracellular compartment (endosome, phagosome, lysosome, or cytosol) in which above mentioned orders of bacteria infect, grow, hide, and go quiescent.

The invention relates to the technical field of biology, in particular to application of a target spot for inhibiting invasion of mycobacterium tuberculosis cells. Specifically, the invention relates to at least one of the following applications of a substance for reducing the content of Rv2185c protein: 1) an application in preparation of a product for treatment or adjuvant treatment of tuberculosis; and 2) application in preparation of products for preventing or inhibiting mycobacterium tuberculosis infection. Protein coded by the Rv2185c gene is located on a mycobacterium tuberculosis membrane and can interact with phospholipids (PI4P, PIP2 and PIP3) on the surface of a host cell, so that phagocytosis of macrophages to mycobacterium tuberculosis is inhibited. Therefore, by taking the Rv2185c gene as a target spot for inhibiting invasion of mycobacterium tuberculosis cells and reducing the content of the Rv2185c protein on a mycobacterium tuberculosis membrane, a new direction can be provided for treating tuberculosis or inhibiting infection of mycobacterium tuberculosis.

The present invention discloses oxazolidinone compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A and E, are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and / or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and / or salt.

Disclosed are dihydroisoxazole compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. Also disclosed are compositions which comprise at least one of these dihydroisoxazole compounds, methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of these dihydroisoxazole compounds and / or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and / or salt.

The present disclose provides a primer, probe, and kit for broad-spectrum detection of mycobacteria and use thereof, relating to the technical field of broad-spectrum detection of mycobacteria; the primer-probe combination including forward primer, reverse primer and probe, the nucleotide sequence of forward primer is shown in SEQ ID NOs. 1 and 2, the nucleotide sequence of reverse primer is shown in SEQ ID NO. 3, and the nucleotide sequence of detection probe is shown in SEQ ID NOs. 4-6. The primer-probe combination provided by the present disclose can detect more than 160 types of mycobacteria, covering a wide range; the detection time is greatly shortened; having strong specificity, and has no cross reaction with non-mycobacterial cells and viral genomes; having high detection sensitivity, with the detection limit reaching 100 CFU / ml and the genome detection limit being 10-20 copies / reaction; having high durability and high resistance to matrix interference.

The present disclosure features compositions and methods for the treatment of actinomycete (e.g., Corynebacteriales) infections caused by mycobacterial cells residing within a host cell (e.g., a mammalian cell, such as an immune cell, e.g., a macrophage or dendritic cell). The compositions and methods involve delivering a mixture of lytic enzymes to specifically target the cell envelope of a group of related bacterial species within intracellular compartments (endosomes, phagosomes, lysosomes, or cytosol) where bacteria of the aforementioned orders infect, grow, hide, and rest.

The disclosure provides the identification and development of a first-in-class, small-molecule inhibitor (Compound 95) of Polyketide synthase 13 (Pks13), a critical node in cell wall biosynthesis for Mycobacterium tuberculosis (Mtb). Cell wall inhibitors are a critical component of TB treatment. Uniquely, the Compound 95 series has been shown to form a covalent adduct with serine residue 801 in the acyltransferase (AT) domain of Pks13. The inhibition of the Pks13 AT domain ultimately leads to disruption of mycolic acid synthesis, which is an essential component of the mycobacterial cell wall. While Pks13 is recognized as a high-value drug target, there are no Pks13 inhibitors in development and Compound 95 represents a new class of inhibitors for TB treatment.

The invention relates to a recombinant Mycobacterium cell for use as a safe and effective vaccine in the prevention of tuberculosis occurrence or recurrence.

The invention belongs to the technical field of bioengineering, and particularly relates to an Mtb8 polyclonal antibody as well as a preparation method and application thereof. The polyclonal antibody is an Mtb8 specific polyclonal antibody obtained by immunizing an animal with cell wall components of mycobacterium tuberculosis, collecting immunized serum and purifying the serum. The polyclonal antibody is only combined with Mtb8 and only reacts with mycobacteria, so that the polyclonal antibody has relatively good specificity and relatively high sensitivity. The polyclonal antibody prepared by the invention can be used for detecting tuberculosis and nontuberculous mycobacterium (NTM) diseases, and is beneficial to improving the accuracy of a detection result.

The present disclosure features compositions and methods for the treatment of actinomycetia (e.g., corynebacteriales) infections, e.g., caused by mycobacterial cells. In one aspect, the disclosure features a composition containing unencapsulated proteins that include one or more of (a) a Lysin A; (b) a Lysin B; (c) an isoamylase; and (d) an α-amylase. The composition optionally further includes a supramolecular structure including one or more (a) a Lysin A; (b) a Lysin B; (c) an isoamylase; and (d) an α-amylase. In another aspect, the invention features a method of treating a bacterial infection in a subject by administering a composition of unencapsulated lytic proteins as described herein to the subject in an amount and for a duration sufficient to treat the bacterial infection, optionally in combination with encapsulated lytic proteins. The encapsulated lytic proteins and the unencapsulated lytic proteins can be in the same or different composition and can be administered simultaneously or sequentially.

The present disclosure relates to compositions and methods for the treatment of actinomycete (e.g., Corynebacteriales) infections caused by, for example, mycobacterial cells. In one aspect, the present disclosure relates to a composition containing an unencapsulated protein comprising one or more of (a) lysin A; (b) lysin B; (c) isoamylase; and (d) α-amylase. The composition may further comprise a supramolecular structure comprising one or more of (a) lysin A; (b) lysin B; (c) isoamylase; and (d) α-amylase. In another aspect, the present invention is a method for treating a bacterial infection in a subject, the method comprising administering to the subject a composition of the unencapsulated lytic protein described herein, optionally in combination with an encapsulated lytic protein, in an amount and for a time sufficient to treat the bacterial infection. The encapsulated lytic protein and the unencapsulated lytic protein can be the same or different compositions and can be administered simultaneously or sequentially.

The invention relates to modified Mycobacterium cells, and their uses as vaccines, and, particularly, modified Bacillus Calmette-Guérin vaccines. The invention extends to the use of the modified vaccines for vaccination applications in a wide range of animals, including cattle and humans. The invention extends to novel antigens, kits and compositions comprising these novel antigens and to their use in diagnosis. The invention also extends to apparatus comprising the modified vaccine and the antigens, and compositions comprising the antigens.

The present invention includes compositions, including epitope megapools, and methods for detecting the presence of: a Mycobacterium, including a latent or active infection, or an immune response relevant to a Mycobacterium infection including T cells responsive to one or more Mycobacterium peptides or proteins from: one or more amino acid sequences selected from any one of those sequences set forth in Tables 1-5 (SEQ ID NOS: 1-718), or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein; a pool of 2 or more peptides; or a polynucleotide that encodes one or more peptides or proteins, or a subsequence, portion, homologue, variant or derivative thereof. The invention further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.

The present invention relates to the field of molecular biology and immunology technology, and specifically discloses an application of a Mycobacterium tuberculosis T cell epitope protein Rv1566c-444. The present invention provides an application of a Mycobacterium tuberculosis T cell epitope protein Rv1566c-444 in the preparation of tuberculosis detection reagents and vaccines; wherein the amino acid sequence of the Mycobacterium tuberculosis T cell epitope protein Rv1566c-444 is shown in SEQ ID NO.4. The Mycobacterium tuberculosis T cell epitope protein Rv1566c-444 of the present invention can reduce false negatives caused by the stimulation of T cells by intrinsic protein antigens of the test kit, thereby improving the detection sensitivity. The cellular immune response is good, and it can be widely used in related fields such as auxiliary diagnosis of tuberculosis, epidemiological monitoring and infection screening, and provides a new idea for the development of new anti-tuberculosis vaccines.

The invention belongs to the technical field of biology, and discloses a detection system and a detection method of mycobacterium tuberculosis and application. In the mycobacterium tuberculosis detection system provided by the invention, magnesium chloride, magnesium sulfate, polyethylene glycol, lysozyme, betaine, lecithin and alkyl trimethyl ammonium bromide are compounded according to the mass ratio of (2-4): (3-5): (40-3000): (0.05-0.2): (650-2500): (50-300): (1-250) to obtain a PCR (Polymerase Chain Reaction) reaction solution, and the PCR reaction solution has excellent splitting capacity on mycobacterium tuberculosis; according to the present invention, in the PCR reaction chamber provided with the magnesium oxide and silver oxide introduced anti-interference layer, the PCR reaction liquid can effectively inhibit the inhibition effect of the mycobacterium tuberculosis cell lysate on the PCR reaction, and can enhance the specific amplification so as to obtain the detection result with characteristics of high reliability and high accuracy; and the kit has a good application prospect in rapid clinical detection of tuberculosis.

The present disclosure features compositions and methods for the treatment of actinomycete (e.g., Corynebacterium) infections, e.g., caused by Mycobacterium cells. In one aspect, the present disclosure features a composition comprising an unencapsulated protein comprising one or more of: (a) lysin A; (b) lysin B; (c) an isoamylase; and (d) an alpha-amylase. The composition optionally further comprises a supramolecular structure comprising one or more of the following: (a) lysin A; (b) lysin B; (c) an isoamylase; and (d) an alpha-amylase. In another aspect, the invention features a method of treating a bacterial infection in a subject by administering to the subject a composition of an unencapsulated cleavage protein as described herein, optionally in combination with an encapsulated cleavage protein, in an amount and duration sufficient to treat the bacterial infection. The encapsulated cleavage proteins and the unencapsulated cleavage proteins can be in the same or different compositions, and can be administered simultaneously or sequentially.

The present application relates to the field of biotechnology, and in particular to an application of a target for inhibiting the invasion of Mycobacterium tuberculosis cells. Specifically, it is at least one of the following applications of a substance that reduces the content of Rv2185c protein: 1) Application in the preparation of products for the treatment or auxiliary treatment of tuberculosis; 2) Application in the preparation of products for the prevention or inhibition of Mycobacterium tuberculosis infection. The protein encoded by the Rv2185c gene is located on the membrane of Mycobacterium tuberculosis and can interact with phospholipids (PI4P, PIP2, PIP3) on the surface of host cells, thereby inhibiting the phagocytosis of Mycobacterium tuberculosis by macrophages. Therefore, with Rv2185c The gene is a target for inhibiting the invasion of Mycobacterium tuberculosis cells. By reducing the content of Rv2185c protein on the membrane of Mycobacterium tuberculosis, it can provide a new direction for the treatment of tuberculosis or the inhibition of Mycobacterium tuberculosis infection.

The present invention relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one dihydroisoxazole compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of a dihydroisoxazole of the invention and / or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and / or salt.